Pharming announces completion of enrolment in Phase II/III study with leniolisib for activated PI3K delta syndrome

June 23, 2021 at 12:00 AM EDT
Supporting Materials:
Pharming announces the successful completion of patient enrolment in the  pivotal Phase II/III triple-blind, randomized, placebo-controlled study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).